Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma

被引:15
作者
Lin, Zhi-Huan [1 ,2 ]
Jiang, Jun-Rong [1 ]
Ma, Xiao-Kun [1 ]
Chen, Jie [1 ]
Li, He-Ping [2 ]
Li, Xing [1 ]
Wu, Xiang-Yuan [1 ]
Huang, Ming-Sheng [3 ,4 ]
Lin, Qu [1 ,4 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Eastern Hosp, Dept Med Oncol, Guangzhou 510630, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Intervent Radiol, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[4] Sun Yat Sen Univ, Guangdong Key Lab Liver Dis Res, Affiliated Hosp 3, Guangzhou 510630, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; Hypoxia-inducible factor-1 alpha (HIF-1 alpha); Transcatheter arterial chemoembolization; VEGF; Prognosis; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; VEGF; EMBOLIZATION; ANGIOGENESIS; EXPRESSION; THERAPY; CANCER;
D O I
10.1007/s10238-020-00667-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Transarterial chemoembolization (TACE) induces a change in serum HIF-1 alpha level in patients with hepatocellular carcinoma (HCC). This study investigated the prognostic value of change in serum HIF-1 alpha following TACE treatment in HCC patients. A total of 61 hepatocellular carcinoma patients treated with TACE were included. Peripheral blood samples were collected within 1 week before and after TACE to determine the serum levels of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor-A (VEGF-A) by enzyme-linked immunosorbent assay (ELISA). Serum HIF-1 alpha change was calculated as follows: increment HIF-1 alpha = (HIF-1 alpha (pre-TACE) - HIF-1 alpha (post-TACE))/HIF-1 alpha (pre-TACE). Likewise, serum VEG-F change was calculated as follows: increment VEG-F = (VEG-F (pre-TACE) - VEG-F(post-TACE))/VEG-F (pre-TACE). Based on the cutoffs (0.25) determined by the maximum Youden's index in receiver operating characteristic analysis, the patients were grouped into the low increment HIF-1 alpha group (< 0.25) and the high increment HIF-1 alpha group (> 0.25). After TACE treatment, HIF-1 alpha was significantly decreased (pre-TACE 1901.62 vs. post-TACE 621.82 pg/ml,P < 0.01) but VEGF-A was significantly increased (pre-TACE 60.80 vs. post-TACE 143.81 pg/ml,P < 0.01). Multivariate logistic regression analysis demonstrated that increment HIF-1 alpha was a prognostic factor (OR = 58.09, 95% CI: 1.59-2127.32, P = 0.027) for the TACE treatment response. Furthermore, multivariate Cox regression analysis revealed that increment HIF-1 alpha was a prognostic factor for progression-free survival (PFS) (HR = 0.30, 95% CI: 0.14-0.66,P = 0.003) and overall survival (OS) (estimated HR = 0.38, 95% CI: 0.16-0.93,P = 0.034). Kaplan-Meier survival analysis showed that the high increment HIF-1 alpha group was more likely to have longer PFS (log-rank test,P = 0.004) and OS (log-rank test,P = 0.002) than the low increment HIF-1 alpha group. The change in serum HIF-1 alpha level following TACE is a prognostic factor associated with the TACE treatment response, PFS, and OS in HCC patients following TACE.
引用
收藏
页码:109 / 120
页数:12
相关论文
共 27 条
[1]   Hepatocellular carcinoma: a review [J].
Balogh, Julius ;
Victor, David, III ;
Asham, Emad H. ;
Burroughs, Sherilyn Gordon ;
Boktour, Maha ;
Saharia, Ashish ;
Li, Xian ;
Ghobrial, R. Mark ;
Monsour, Howard P., Jr. .
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2016, 3 :41-53
[2]   Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day [J].
Boulin, M. ;
Delhom, E. ;
Pierredon-Foulongne, M. -A. ;
Cercueil, J. -P. ;
Guiu, B. .
DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2015, 96 (06) :607-615
[3]   Clinical significance of serum miR-768-3p in HBV-related hepatocellular carcinoma and its potential mechanism [J].
Cao, Chunyu ;
Wang, Changjiang .
CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 20 (04) :569-576
[4]   Systemic treatment for inoperable pancreatic adenocarcinoma: review and update [J].
Chan, Stephen L. ;
Chan, Sin T. ;
Chan, Eric H. ;
He, Zhe-Xi .
CHINESE JOURNAL OF CANCER, 2014, 33 (06) :267-276
[5]   Over-Expression of Semaphorin4D, Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor Is Related to Poor Prognosis in Ovarian Epithelial Cancer [J].
Chen, Ying ;
Zhang, Lei ;
Pan, Yi ;
Ren, Xiubao ;
Hao, Quan .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (10) :13264-13274
[6]   Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α [J].
Freedman, SJ ;
Sun, ZYJ ;
Poy, F ;
Kung, AL ;
Livingston, DM ;
Wagner, G ;
Eck, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (08) :5367-5372
[7]   Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization [J].
Guo, Jian-hai ;
Zhu, Xu ;
Li, Xiao-ting ;
Yang, Ren-jie .
CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (01) :36-43
[8]   Association between the expression of HIF-1α and VEGF and prognostic implications in primary liver cancer [J].
Guo, L. Y. ;
Zhu, P. ;
Jin, X. P. .
GENETICS AND MOLECULAR RESEARCH, 2016, 15 (02)
[9]   The relationship between the preoperative plasma level of HIF-1α and clinic pathological features, prognosis in non-small cell lung cancer [J].
He, Jiabei ;
Hu, Ying ;
Hu, Mingming ;
Zhang, Siyi ;
Li, Baolan .
SCIENTIFIC REPORTS, 2016, 6
[10]   Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization [J].
Hsieh, Ming-Yen ;
Lin, Zu-Yau ;
Chuang, Wan-Long .
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2011, 27 (08) :314-322